Why the study?
Does TCV-309 reduce arrhythmias and improve functional recovery during myocardial reperfusion in a canine model?
Does TCV-309 reduce arrhythmias and improve functional recovery during myocardial reperfusion in a canine model?
The platelet-activating-factor antagonist TCV-309 reduces reperfusion arrhythmias but does not improve functional recovery in a canine model of brief coronary occlusion.
No takes yet. Share an insight, caveat, or question.
TCV-309 may reduce reperfusion arrhythmias without functional recovery in canines; leaves open translation of PAF antagonism to human ischemia-reperfusion injury.
Mura et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: